Through interactive, quantitative live and virtual double-blinded case-based sessions followed by a national key opinion leader data-focused discussion, Challenging Cases offers a window into how oncologists select treatment options, balance clinical considerations, and respond to complex patient scenarios, providing insight into the factors shaping real-world treatment decisions.
Specialty Dispensing Insights delivers practice, clinic, and physician level perspective on oral therapy use within from medically integrated dispensing (MID) pharmacies, including dose and days’ supply metrics, ZIP based activity, competitive prescribing, and trends in new patient starts. These insights offer clear visibility into how oral therapies are utilized within MID practices, helping teams understand the unique prescribing dynamics, geographic variation, and competitive activity across real-world community settings.
SiteALERT delivers timely, real‑world insight into how physicians are treating patients, helping teams quickly understand where their brand is being used and where unmet or under utilized opportunities exist within the competitive landscape. These behavioral patterns make it easier to focus marketing and sales efforts where they matter—guiding outreach that aligns naturally with the way clinicians are practicing today.
This insight piece breaks down how three different specialty pharmacy network structures relate to prescription capture patterns in medically integrated dispensing settings. You’ll learn what distinguishes each type of limited distribution model, how those differences are seen in internal vs. external dispensing behavior, and what the data suggests about the way prescriptions flow across networks. It’s designed to help teams better understand distribution models and think more clearly about how network design may shape dispensing dynamics.
This insight piece explores how treatment patterns in bladder cancer have shifted as immunotherapy options have expanded in community oncology. You’ll learn how combination regimens such as enfortumab vedotin–pembrolizumab have become more widely used, what real world data shows about changes in first line treatment choices, and how duration on therapy differs across approaches. It offers a real-world look at how community providers are adapting to new evidence and incorporating emerging options into care.